WORLD LEADING PARASITOLOGY AND MYCOLOGY TEST KITS
RAPID LATERAL FLOW TEST FOR BRUCELLA CANIS NOW AVAILABLE
Q-TOX FACTOR-X ACTIVATOR RVV-X NOW AVAILABLE
COST EFFECTIVE VETERINARY DIAGNOSTICS NOW AVAILABLE
Featured Products
Our Product Ranges
Recieve our latest news
Sign up to our newsletterOur Company
With over 30 years of trading experience, Quadratech Diagnostics Limited has always been and remains committed to providing the highest quality state-of-the-art medical diagnostic and research products. Since the company was founded in 1990, we have expanded to encompass the following main areas: Haemostasis, Antigens, Antibodies and Toxins, Rapid and POC Tests, Parasitology and Veterinary.
Quadratech Diagnostics Limited is a corporate member of the Institute of Biomedical Scientists (IBMS) and the British Society for Haemostasis and Thrombosis (BSHT). We are a recognised supplier to the UK National Health Service (NHS), the Irish Health Service Executive (HSE), private laboratories, the UK pharmaceutical industry, and university research groups. Quadratech Diagnostics Limited became incorporated as a limited company in 1998 and is ISO 9001:2015 certified.
Our Product Brands
Latest News
UK NEQAS for Laboratory and Clinical Haemostasis 2025 Reflections
UK NEQAS for Laboratory and Clinical Haemostasis 2025: Key Takeaways and Reflections by Quadratech Diagnostics Team In June, we were delighted to sponsor UK NEQAS Blood Coagulation Annual Scientific Meeting in Sheffield. We truly valued the opportunity to meet with our existing customers and to welcome new participants interested in our diagnostic solutions. The two-day […]
Haemostasis Journal Club September 2025
Keep informed about evolving science and clinical practice with our compilation of the latest studies, guidelines, and perspectives in haemostasis. GUIDELINES Barrett WJ, Kaucher KA, Orpet RE, et al. Tranexamic acid in trauma: A joint position statement and resource document of NAEMSP, ACEP, and ACS-COT. J Trauma Acute Care Surg. 2025;99(3):357-363. doi:10.1097/TA.0000000000004727 Lier H, Goossen K, […]
Haemostasis Q3 2025 News
Our round-up of the latest developments from across the haemostasis industry for Q3 2025. REGULATORY Novo Nordisk’s Alhemo (concizumab-mtci, a tissue factor pathway inhibitor antagonist) injection received positive opinion by the EMA CHMP, recommending label expansion to include the treatment of severe haemophilia A and moderate or severe haemophilia B without inhibitors (25 Jul) Kedrion […]
